Balyasny Asset Management
ANRO icon

Balyasny Asset Management’s Alto Neuroscience ANRO Stock Holding History

Balyasny Asset Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$722K Buy
32,111
+20,991
+189% +$389K ﹤0.01% 2215
2025
Q4 		$198K Buy
+11,120
New +$140K ﹤0.01% 2887

Other funds holding ANRO

AWG
Alpha Wave Global New York $791M AUM 113.77% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $416M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Balyasny Asset Management's ANRO Position: Q1 2026 in Review

Balyasny Asset Management increased its Alto Neuroscience (ANRO) stake by 189% in Q1 2026, buying an estimated $389K and bringing the position to 32,111 shares worth $722K. The position accounts for ﹤0.01% of the portfolio, ranked #2215.

Balyasny Asset Management first reported a position in ANRO in Q4 2025 and has held it in 2 quarters since. 110 funds tracked by Wall St. Rank hold ANRO as of Q1 2026.

  • Balyasny Asset Management held 32,111 shares of Alto Neuroscience worth $722K as of Q1 2026.
  • Balyasny Asset Management bought 20,991 Alto Neuroscience shares in Q1 2026, an estimated $389K.
  • Alto Neuroscience made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2215 holding.
  • Balyasny Asset Management first reported a position in Alto Neuroscience in Q4 2025 and has held it in 2 quarters since.
  • 110 funds tracked by Wall St. Rank held Alto Neuroscience as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.